Dendrite Announces Grants under New Hire Authorization

  
    
  
  
    
      Pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv), as amended as of 
      October 14, 2003, Dendrite International, Inc. (NASDAQ: DRTE) today 
      announced that stock options covering an aggregate of 40,000 shares of 
      common stock were granted to one non-executive officer employee on 
      November 1, 2006; options covering an aggregate of 7,500 shares were 
      granted to one non-executive officer employee on October 30, 2006; 
      options covering an aggregate of 40,000 shares of common stock were 
      granted to three non-executive officer employees on October 23, 2006; 
      and options covering an aggregate of 60,000 shares were granted to one 
      non-executive officer employee on September 25, 2006.
    
    
      All such option grants were made under the Company's New Hire 
      Authorization as inducements to entering into employment with the 
      Company. All options granted include a ten-year duration and an exercise 
      price equal to the closing price of Dendrite's stock on the business day 
      immediately preceding the date of grant. The vesting schedule for the 
      options is as follows: (i) twenty-five percent (25%) of the options 
      shall first become exercisable on the first anniversary of date of grant 
      and (ii) the remaining seventy-five percent (75%) shall become 
      exercisable pro rata over the following three (3) year period, on a 
      monthly basis, commencing on the first anniversary of the date of grant 
      and ending on the fourth anniversary of the date of grant.
    
    
      About Dendrite
    
    
      Founded in 1986, Dendrite International, Inc. enables sales, marketing, 
      clinical and compliance solutions for the global pharmaceutical 
      industry. The Company's clients are located in more than 50 countries 
      and include the world's top 20 pharmaceutical companies. For more 
      information, please visit www.dendrite.com.
    
    
      Note: Dendrite® is a registered trademark of 
      Dendrite International, Inc. FORWARD LOOKING INFORMATION: This document 
      contains forward-looking statements that may be identified by such 
      forward-looking terminology as "expect," "believe," "anticipate," 
      "will," "intend," "plan," "target," "outlook," "guidance," and similar 
      statements or variations. Such forward-looking statements are based on 
      our current expectations, estimates, assumptions and projections and 
      involve significant risks and uncertainties, including risks which may 
      result from our dependence on the pharmaceutical industry; our fixed 
      expenses in relation to fluctuating revenues and variations in 
      customers' budget cycles; dependence on certain major customers, 
      including the risk associated with our largest customer's plans to 
      transition a significant portion of its U.S. sales force effectiveness 
      services needs; fluctuations in quarterly revenues due to lengthy sales 
      and implementation cycles; our ability to successfully implement our 
      Operational Effectiveness program and to achieve the cost savings in the 
      amounts and time periods expected or budgeted; changes in demand for our 
      products and services attributable to any weakness experienced in the 
      economy or mergers, acquisitions and consolidations in the 
      pharmaceutical industry; risks associated with foreign currency 
      fluctuations as they affect our non-U.S. operations; risks associated 
      with our expanded international operations and our ability to adopt and 
      respond successfully to the unique risks involved in our non-U.S. 
      operations; any difference between estimated and actual stock option 
      expense; and risks associated with reviewing strategic options and with 
      any transaction occurring or being consummated at any subsequent time. 
      Other important factors that should be reviewed and carefully considered 
      are included in the Company's 10-K under "Factors That May Affect Future 
      Results" and its 10-Qs and other reports filed with the SEC. Actual 
      results may differ materially. The Company assumes no obligation for 
      updating any such forward-looking statements to reflect actual results, 
      changes in expectations or assumptions or other changes affecting such 
      forward-looking statements, even if such results or changes make it 
      clear that any such projected results will not be achieved. Any outlook 
      and other forward-looking information is as of the date of this release 
      only. At any such time in the future as the Company may provide revenue, 
      earnings and other outlook information, prior related outlook should no 
      longer be considered current. Our outlook and other forward-looking 
      information do not take into account or reflect any possible future 
      acquisitions, dispositions or similar transactions which may occur.
    
  
Pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv), as amended
as of October 14, 2003, Dendrite International, Inc. (NASDAQ: DRTE)
today announced that stock options covering an aggregate of 40,000
shares of common stock were granted to one non-executive officer
employee on November 1, 2006; options covering an aggregate of 7,500
shares were granted to one non-executive officer employee on October
30, 2006; options covering an aggregate of 40,000 shares of common
stock were granted to three non-executive officer employees on October
23, 2006; and options covering an aggregate of 60,000 shares were
granted to one non-executive officer employee on September 25, 2006.

   All such option grants were made under the Company's New Hire
Authorization as inducements to entering into employment with the
Company. All options granted include a ten-year duration and an
exercise price equal to the closing price of Dendrite's stock on the
business day immediately preceding the date of grant. The vesting
schedule for the options is as follows: (i) twenty-five percent (25%)
of the options shall first become exercisable on the first anniversary
of date of grant and (ii) the remaining seventy-five percent (75%)
shall become exercisable pro rata over the following three (3) year
period, on a monthly basis, commencing on the first anniversary of the
date of grant and ending on the fourth anniversary of the date of
grant.

   About Dendrite

   Founded in 1986, Dendrite International, Inc. enables sales,
marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.

   Note: Dendrite(R) is a registered trademark of Dendrite
International, Inc. FORWARD LOOKING INFORMATION: This document
contains forward-looking statements that may be identified by such
forward-looking terminology as "expect," "believe," "anticipate,"
"will," "intend," "plan," "target," "outlook," "guidance," and similar
statements or variations. Such forward-looking statements are based on
our current expectations, estimates, assumptions and projections and
involve significant risks and uncertainties, including risks which may
result from our dependence on the pharmaceutical industry; our fixed
expenses in relation to fluctuating revenues and variations in
customers' budget cycles; dependence on certain major customers,
including the risk associated with our largest customer's plans to
transition a significant portion of its U.S. sales force effectiveness
services needs; fluctuations in quarterly revenues due to lengthy
sales and implementation cycles; our ability to successfully implement
our Operational Effectiveness program and to achieve the cost savings
in the amounts and time periods expected or budgeted; changes in
demand for our products and services attributable to any weakness
experienced in the economy or mergers, acquisitions and consolidations
in the pharmaceutical industry; risks associated with foreign currency
fluctuations as they affect our non-U.S. operations; risks associated
with our expanded international operations and our ability to adopt
and respond successfully to the unique risks involved in our non-U.S.
operations; any difference between estimated and actual stock option
expense; and risks associated with reviewing strategic options and
with any transaction occurring or being consummated at any subsequent
time. Other important factors that should be reviewed and carefully
considered are included in the Company's 10-K under "Factors That May
Affect Future Results" and its 10-Qs and other reports filed with the
SEC. Actual results may differ materially. The Company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in expectations or assumptions or other
changes affecting such forward-looking statements, even if such
results or changes make it clear that any such projected results will
not be achieved. Any outlook and other forward-looking information is
as of the date of this release only. At any such time in the future as
the Company may provide revenue, earnings and other outlook
information, prior related outlook should no longer be considered
current. Our outlook and other forward-looking information do not take
into account or reflect any possible future acquisitions, dispositions
or similar transactions which may occur.